Acinetobacter baumannii complex-Introduction, Morphology, Pathogenicity, Lab Diagnosis, Treatment, Prevention, and Keynotes

Introduction

Acinetobacter baumannii complex is a group of Gram-negative, non-fermenting bacilli known for causing healthcare-associated infections. It includes closely related species like A. baumannii, A. pittii, A. nosocomialis, and A. calcoaceticus. This complex thrives in hospital environments and poses a serious challenge due to its multidrug resistance and persistence on surfaces.

Morphology

• Gram-negative coccobacilli (short rods)
• Non-motile and oxidase-negative
• Catalase-positive
• Appears as diplococci under Gram stain, often confused with Neisseria or Moraxella
• Forms smooth, opaque, dome-shaped colonies on nutrient agar or MacConkey agar (non-lactose fermenting)

Pathogenicity

• Causes opportunistic infections, especially in immunocompromised patients
• Major infections: ventilator-associated pneumonia (VAP), bloodstream infections (BSI), urinary tract infections, wound infections, and meningitis
• Adheres to epithelial cells and abiotic surfaces via pili and outer membrane proteins
• Produces enzymes like β-lactamases, and forms biofilms that aid in resistance and survival
• Known for its role in outbreaks in ICU settings

Laboratory Diagnosis

1. Specimen types: Blood, sputum, tracheal aspirates, wound swabs, urine
2. Culture: Grows well on blood agar and MacConkey agar
3. Gram stain: Shows Gram-negative coccobacilli
4. Biochemical tests: Oxidase-negative, catalase-positive, non-motile, glucose non-fermenter
5. MALDI-TOF MS: Rapid and accurate identification
6. Molecular methods (PCR, sequencing): Used to differentiate species within the complex
7. Antibiotic susceptibility testing (AST): Essential due to frequent multidrug resistance

Treatment

• Multidrug resistance is common (MDR, XDR, and PDR strains)
• Preferred agents (depending on susceptibility):
  • Carbapenems (e.g., meropenem) — although resistance is increasing
  • Polymyxins (colistin, polymyxin B) are often last-resort drugs.
  • Tigecycline, minocycline, sulbactam, cefiderocol — in resistant strains
• Combination therapy may be considered in severe infections
• Antimicrobial stewardship and local antibiogram guide therapy

Prevention

• Strict hand hygiene and contact precautions
• Environmental disinfection (it survives on surfaces for weeks)
• Surveillance and cohorting during outbreaks
• Rational antibiotic use to prevent resistance development
• Use of sterile devices and aseptic techniques in ICUs

Keynotes

• A. baumannii complex causes severe infections in critically ill patients
• Its remarkable environmental resilience and antibiotic resistance make it a “red alert” pathogen (WHO priority list)
• Early identification and AST-guided treatment are crucial
• Molecular tools help differentiate between species in the complex
• Prevention hinges on infection control and antibiotic policy compliance
• Late lactose-fermenting, gram-negative coccobacilli, non-motile, are the key features of Acinetobacter.

Further Readings

• https://www.ncbi.nlm.nih.gov/books/NBK430784/
• https://emedicine.medscape.com/article/236891-overview
• https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/acinetobacter
• https://www.nature.com/articles/nrmicro1789
• https://journals.asm.org/doi/10.1128/cmr.00058-16
• https://academic.oup.com/femspd/article/71/3/292/475786
• https://www.vdh.virginia.gov/epidemiology/epidemiology-fact-sheets/acinetobacter-infection/
• https://www.uptodate.com/contents/acinetobacter-infection-epidemiology-microbiology-pathogenesis-clinical-features-and-diagnosis/print
• https://pmc.ncbi.nlm.nih.gov/articles/PMC2946687/